The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines

References

• Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010;CD000545.
   PubMedGoogle Scholar
• Oussalah A, Danese S, Peyrin-Biroulet L. Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. Curr Drug Targets 2010;11:156–75.
   PubMedGoogle Scholar
• Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929–36.
   PubMed Web of Science ®Google Scholar
• Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol 2010;24:167–82.
   PubMed Web of Science ®Google Scholar
• Duricova D, Pedersen N, Elkjaer M, Gamborg M, Munkholm P, Jess T. Overall and cause-specific mortality in Crohn's disease: a meta-analysis of population-based studies. Inflamm Bowel Dis 2010;16:347–53.
   PubMed Web of Science ®Google Scholar
• Aberra FN, Lichtenstein GR. Methods to avoid infections in patients with inflammatory bowel disease. Inflamm Bowel Dis 2005;11:685–95.
   PubMed Web of Science ®Google Scholar
• Sands BE, Cuffari C, Katz J, Kugathasan S, Onken J, Vitek C, Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004;10:677–92.
   PubMed Web of Science ®Google Scholar
• Rahier JF, Ben-Horin S, Chowers Y, Conlon C, Munter PD, D'Haens G, European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis 2009;3:47–91.
   Google Scholar
• Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Med Clin North Am 2010;94:1–18.
   PubMedGoogle Scholar
• Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383–95.
   PubMed Web of Science ®Google Scholar
• D'Haens GR. Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol 2010;7:86–92.
   PubMed Web of Science ®Google Scholar
• Fiore AE, Shay DK, Haber P, Iskander JK, Uyeki TM, Mootrey G, Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep 2007;56:1–54.
   PubMedGoogle Scholar
• Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006;101:1834–40.
   PubMed Web of Science ®Google Scholar
• Danerseau AM, Robinson JL. Efficacy and safety of measles, mumps, rubella and varicella live viral vaccines in transplant recipients receiving immunosuppressive drugs. World J Pediatr 2008;4:254–8.
   PubMedGoogle Scholar
• Lu Y, Bousvaros A. Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy. J Pediatr Gastroenterol Nutr 2010;50:562–5.
   PubMed Web of Science ®Google Scholar
• Lu Y, Jacobson DL, Ashworth LA, Grand RJ, Meyer AL, McNeal MM, Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol 2009;104:444–53.
   PubMed Web of Science ®Google Scholar
• Melmed GY, Agarwal N, Frenck RW, Ippoliti AF, Ibanez P, Papadakis KA, Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:148–54.
   PubMed Web of Science ®Google Scholar
• Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:851–6.
   PubMed Web of Science ®Google Scholar
• Rahier JF, Papay P, Salleron J, Sebastian S, Marzo M, Peyrin-Biroulet L, H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 2011;60:456–62.
   PubMed Web of Science ®Google Scholar
• Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008;57:549–58.
   PubMed Web of Science ®Google Scholar
• Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363–5.
   PubMed Web of Science ®Google Scholar
• Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis 2010;16:925–32.
   PubMed Web of Science ®Google Scholar
• Loras C, Gisbert JP, Minguez M, Merino O, Bujanda L, Saro C, Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010;59:1340–6.
   PubMed Web of Science ®Google Scholar